INVA Stock Summary and Trading Ideas (Innoviva | NASDAQ:INVA)

Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.

Innoviva trades on the NASDAQ stock market under the symbol INVA.

As of September 4, 2026, INVA stock price declined to $21.33 with 441,962 million shares trading.

INVA has a beta of -0.28, meaning it tends to be less sensitive to market movements. INVA has a correlation of 0.01 to the broad based SPY ETF.

INVA has a market cap of $1.54 billion. This is considered a Small Cap stock.

Last quarter Innoviva reported $120 million in Revenue and -$1.14 earnings per share. This beat revenue expectation by $8 million and missed earnings estimates by -$1.65.

In the last 3 years, INVA traded as high as $25.15 and as low as $12.22.

The top ETF exchange traded funds that INVA belongs to (by Net Assets): VTI, VB, VBR, AVUV, PJP.

INVA has underperformed the market in the last year with a return of +2.0%, while the SPY ETF gained +19.8%. In the last 3 month period, INVA fell short of the market, returning -3.7%, while SPY returned +2.0%. However, in the most recent 2 weeks INVA has outperformed the stock market by returning +1.2%, while SPY returned +0.6%.

INVA support price is $21.05 and resistance is $21.65 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INVA shares will trade within this expected range on the day.